| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
* Department of Veterans Affairs Medical Center, White River Junction, VT 05001;
Department of Medicine, Dartmouth Medical School, Hanover, NH 03756; and
Department of Exploratory Sciences, Biogen, Cambridge, MA 02142
A lymphotoxin-
(LT) receptor-Ig fusion protein (LTR-Ig) was used to evaluate the importance of the lymphotoxin/LIGHT axis in the development and perpetuation of arthritis. Prophylactic treatment with the inhibitor protein LTR-Ig blocked the induction of collagen-induced arthritis in mice and adjuvant arthritis in Lewis rats. Treatment of mice with established collagen-induced arthritis reduced the severity of arthritic symptoms and joint tissue damage. However, in a passive model of anti-collagen Ab-triggered arthritis, joint inflammation was not affected by LTR-Ig treatment precluding LT/LIGHT involvement in the very terminal immune complex/complement/FcR-mediated effector phase. Collagen-II and Mycobacterium-specific T cell responses were not impaired, yet there was evidence that the overall response to the mycobacterium was blunted. Serum titers of anti-collagen-II Abs were reduced especially during the late phase of disease. Treatment with LTR-Ig ablated follicular dendritic cell networks in the draining lymph nodes, suggesting that impaired class switching and affinity maturation may have led to a decreased level of pathological autoantibodies. These data are consistent with a model in which the LT/LIGHT axis controls microenvironments in the draining lymph nodes. These environments are critical in shaping the adjuvant-driven initiating events that impact the subsequent quality of the anti-collagen response in the later phases. Consequently, blockade of the LT/LIGHT axis may represent a novel approach to the treatment of autoimmune diseases such as rheumatoid arthritis that involve both T cell and Ab components.
Related articles in The JI:
This article has been cited by other articles:
|
|
 |
|
  M. Pierer, A. Schulz, M. Rossol, E. Kendzia, D. Kyburz, H. Haentzschel, C. Baerwald, and U. Wagner Herpesvirus Entry Mediator-Ig Treatment during Immunization Aggravates Rheumatoid Arthritis in the Collagen-Induced Arthritis Model J. Immunol., March 1, 2009; 182(5): 3139 - 3145. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Pierer, F. Brentano, J. Rethage, U. Wagner, H. Hantzschel, R. E. Gay, S. Gay, and D. Kyburz The TNF superfamily member LIGHT contributes to survival and activation of synovial fibroblasts in rheumatoid arthritis Rheumatology, July 1, 2007; 46(7): 1063 - 1070. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. E. Summers-deLuca, D. D. McCarthy, B. Cosovic, L. A. Ward, C. C. Lo, S. Scheu, K. Pfeffer, and J. L. Gommerman Expression of lymphotoxin-{alpha}{beta} on antigen-specific T cells is required for DC function J. Exp. Med., May 14, 2007; 204(5): 1071 - 1081. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Liao, K. Bentley, M. Lebrun, W. Lesslauer, F. H. Ruddle, and N. H. Ruddle Transgenic LacZ under control of Hec-6st regulatory sequences recapitulates endogenous gene expression on high endothelial venules PNAS, March 13, 2007; 104(11): 4577 - 4582. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. J. Perper, B. Browning, L. C. Burkly, S. Weng, C. Gao, K. Giza, L. Su, L. Tarilonte, T. Crowell, L. Rajman, et al. TWEAK Is a Novel Arthritogenic Mediator J. Immunol., August 15, 2006; 177(4): 2610 - 2620. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. K. Chin, M. Zhu, P. A. Christiansen, W. Liu, C. Ware, L. Peltonen, X. Zhang, L. Guo, S. Han, B. Zheng, et al. Lymphotoxin Pathway-Directed, Autoimmune Regulator-Independent Central Tolerance to Arthritogenic Collagen J. Immunol., July 1, 2006; 177(1): 290 - 297. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. G. Levisetti, A. Suri, K. Frederick, and E. R. Unanue Absence of Lymph Nodes in NOD Mice Treated With Lymphotoxin-{beta} Receptor Immunoglobulin Protects From Diabetes Diabetes, December 1, 2004; 53(12): 3115 - 3119. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Stopfer, D. N. Mannel, and T. Hehlgans Lymphotoxin-{beta} Receptor Activation by Activated T Cells Induces Cytokine Release from Mouse Bone Marrow-Derived Mast Cells J. Immunol., June 15, 2004; 172(12): 7459 - 7465. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
